炎症性肠病采取美沙拉嗪结合双歧杆菌三联活菌治疗对DAI评分及TNF-α、IL-8、IL-23水平的影响  

Effects of mesalazine combined with bifidobacterium triad on DAI score and TNF-α,IL-8,IL-23 levels in inflammatory bowel disease

作　　者：李清福 Li Qingfu(Changsha Central Hospital Affiliated to Nanhua University,Changsha,Hunan 410004,China)

机构地区：[1]南华大学附属长沙中心医院,湖南长沙410004

出　　处：《首都食品与医药》2023年第21期49-52,共4页Capital Food Medicine

摘　　要：目的分析炎症性肠病行美沙拉嗪结合双歧杆菌三联活菌方案治疗的有效性及对患者炎症表达、DAI评分的改善价值.方法研究样本为2020年1月-2022年12月期间于南华大学附属长沙中心医院诊治的80例炎症性肠病患者,用计算机随机分组法将其均分为对照组与观察组.对照组实施美沙拉嗪单药治疗,观察组在对照组的基础上联合双歧杆菌三联活菌片治疗,观察比较两组患者的治疗效果、炎症指标、疾病活动指数以及药物不良反应.结果观察组患者的临床治疗有效率显著高于对照组,组间差异具有统计学意义(P<0.05);治疗前两组患者的IL-6、IL-8、IL-23、TNF-α、SOD炎症指标并无差异,而在治疗后患者的IL-6、IL-8、IL-23、TNF-α均降低,SOD升高,且观察组的IL-6、IL-8、IL-23、TNF-α低于对照组,SOD高于对照组,组间差异具有统计学意义(P<0.05);治疗前两组患者的便血、黏膜炎症、腹泻、便秘、疼痛ADI指标并无差异,而在治疗后患者的相关评分均降低,且观察组的便血、黏膜炎症、腹泻、便秘、疼痛ADI评分低于对照组,组间差异具有统计学意义(P<0.05);观察组药物不良反应发生率高于对照组,但组间差异无统计学意义(P>0.05).结论炎症性肠病行美沙拉嗪结合双歧杆菌三联活菌方案可显著提升患者的治疗效果,改善患者的炎症表达与疾病活动指数,且药物安全性较高,具有重要应用价值.Objective To analyze the efficacy of mesalazine combined with bifidobacterium triple viable regimen in patients with inflammatory bowel disease and the improvement value of inflammatory expression and DAI score.Methods 80 patients with inflammatory bowel disease diagnosed and treated in our hospital from January 2020 to December 2022 were randomly divided into control group and observation group.The control group was treated with monomesalazine,and the observation group was combined with bifidobacterium live tablets on the basis of the control group.The therapeutic effects,inflammatory indicators,disease activity index and adverse drug reactions of the two groups were observed and compared.Results The clinical effective rate of observation group was significantly higher than that of control group,and the difference between groups was statistically significant(P<0.05).There was no difference in IL-6,IL8,IL-23,TNF-αand SOD inflammation indexes between the two groups before treatment,while IL-6,IL-8,IL-23 and TNF-αdecreased and SOD increased after treatment,and IL-6,IL-8,IL-23 and TNF-αin the observation group were lower than those in the control group.SOD was higher than that in control group,and the difference between groups was statistically significant(P<0.05).ADI indexes of hematostoecium,mucosal inflammation,diarrhea,constipation,and pain showed no difference between the two groups before treatment,while the relevant scores of the two groups were decreased after treatment,and ADI scores of hematostoecium,mucosal inflammation,diarrhea,constipation,and pain in the observation group were lower than those in the control group,with statistical significance(P<0.05).The incidence of adverse drug reactions in observation group was higher than that in control group,but there was no statistical significance between groups(P>0.05).Conclusion Mesalazine combined with bifidobacterium triple live regimen in inflammatory bowel disease can significantly improve the therapeutic effect of patients,improve the inflammatory ex

关 键 词：炎症性肠病 美沙拉嗪 双歧杆菌三联活菌片 安全性 炎症 疾病活动指数 

分 类 号：R574[医药卫生—消化系统]